1. Introduction {#s0005}
===============

Skin is a protective barrier for the human body against the environmental attacks such as infections, injuries and incisions. A wound can be described as the deterioration of anatomical and functional integrity of the epithelial tissue of the skin. Acute, chronic, dry or infected wound types may develop due to various physical and mechanical factors, or different reasons such as animal bites, sharp object injuries and trauma ([@b0175], [@b0060]). Wound healing has various processes such as coagulation, inflammation, collagen production, and epithelial formation. After the platelets contact with collagen in wound area, platelets release clotting factor and growth factors. After that, neutrophils migrate to the wound site and remove the microbes from damaged tissue. The macrophages are also contributing to this phase. Microorganisms can cause the release of pro-inflammatory cytokines such as interleukin-1 and TNF-alfa in inflammatory phase. If this situation persists for a long time, the wound may enter a chronic state and fail to heal angiogenesis, granulation tissue production, collagen deposition, and epithelialization occur in the proliferative phase. The final stage of wound healing is maturation. In this phase, collagen cross-linking, remodeling, and wound contraction occur ([@b0150], [@b0155], [@b0085]).

It is known that some plants or ingredients which affect one or more of these stages, especially topically, are used for wound care in folk medicine ([@b0055], [@b0065]). Medical plants contain different biologically active compounds most of which are known as flavonoids. Flavonoids are a large group of phenolic compounds which are widely distributed in the plant kingdom. Vitexin (8-β-D-glucopyranosyl-apigenin), a C-glycosylated flavone, present in various medicinal and other plants such as *Crataegus* and *Vitex* spp., *Passiflora* spp., *Pennisetum glaucum* R. Br., *Phyllostachys nigra*, Munro (bamboo leaves), has showed different pharmacological activities including antinociceptive (Demir [@b0190], [@b0250]), anti-oxidant ([@b0140]), antispasmodic ([@b0080]), anti-inflammatory ([@b0030]), antiviral, antibacterial ([@b0025]) and cardioprotective ([@b0035]) effects. It has been reported that vitexin could be inhibited productions of NO, TNF-alfa, and myeloperoxidase releasing from activated human peripheral blood neutrophils ([@b0185]). And also, [@b0030] have revealed that vitexin has free-radical scavenger ability and inhibited the production of hyperalgesic cytokines such as TNF-α, IL-1β, IL-6. These molecules cause the release of adhesion molecules, such as selectins and integrins, and thus affect many ways of tissue repair, such as angiogenesis and re-epithelization ([@b0085]).

Chitosan is a biocompatible, biodegradable, non-irritant and non-toxic amino polysaccharide obtained by deacetylation of chitin. It is convenient for pharmaceutical and biomedical applications. It is informed that chitosan has antibacterial, anti-inflammatory and antioxidant effects besides tissue-adhesive property due to its polycationic nature and makes a good wound healing material ([@b0110], [@b0020], [@b0195]). It was reported that simulation of the migration of polymorphonuclear as well as mononuclear cells and acceleration of the re-epithelization and normal skin regeneration is the mechanism of action of chitosan in tissue engineering ([@b0070]). Based on this information, it is thought that the combination of vitexin and chitosan, which have similar properties, in tissue repair will accelerate recovery. In the present study, it is aimed to investigate the wound healing effect of formulation prepared as chitosan-based gel with vitexin *in vivo* and *in vitro*.

2. Material and methods {#s0010}
=======================

2.1. Materials {#s0015}
--------------

Vitexin, chitosan (highly viscous;2-amino-2-deoxy-(14)-β-D-glucopyranan, high molecular weight with 800--2000 cPs viscosity values with\> 75% deacetylated), acetic acid, Dulbecco\'s Modified Eagle\'s Medium (DMEM) Fetal Bovine Serum (FBS), penicillin-- streptomycin (10,000 units penicillin and 10 mg streptomycin/mL), 0.25% (w/v) Trypsin-EDTA solution, Phosphate Buffered Saline (PBS), Thiazolyl Blue Tetrazolium Bromide (MTT) and Spectrophotometry-grade Dimethyl Sulfoxide (DMSO) were purchased from Sigma-Aldrich (Germany). CytoSelect™ 24-Well Wound Healing Assay was purchased from Cell Bioblas INC, USA.

2.2. Formulations {#s0020}
-----------------

### 2.2.1. Preparation of the chitosan gel formulations {#s0025}

During the pre-formulation studies, blank formulations and drug loaded formulations were prepared. Gel formulations were prepared with three different chitosan concentrations (1.0% \[R1\]; 1.5% \[R2\]; 2% \[R3\] w/v). Briefly, chitosan was dissolved in acetic acid solution (0.5%, v/v) under a magnetic stirrer at 250 rpm for 4 h. For the drug loaded formulations, vitexin was briefly dissolved in 50 µL DMSO and then added up to the final concentration of 10 mg mL^−1^ of the transparent chitosan solution. Formulations were kept at room temperature overnight in well closed vials for the removal of air bubbles.

### 2.2.2. pH analyses {#s0030}

pH values of the formulations prepared were recorded by a WTW Profi Lab (pH 597, Weilheim, Germany) at 25 ± 1 °C. The pH values of all formulations were analyzed at the 0th time. Depending on the result of 4.1 ± 0.1 pH value, R1 formulation (chitosan-based gel formulation containing vitexin) was selected as the suitable formulation for *in vivo* studies. All analyses were repeated in triplicate. R1 and F1 (blank formulation-vitexin-free chitosan) formulations were kept at three different conditions (25 ± 1 ◦C, 4 ± 1 ◦C, and 40 ± 1 ◦C + 60% Relative Humidity (RH)) for better evaluation of the stability of the chitosan gel during the storage period of one-month ([@b0050], [@b0235]).

### 2.2.3. Rheological analyses {#s0035}

For better evaluation of the stability and spreadability capacity of the gel formulations prepared rheological behaviors of the formulations were determined by a cone plate rheometer (Brookfield RVDV-III + CP, Middleboro, USA). Briefly, about 0.5 g of the tested formula was applied to the plate and the measurements were carried out at 250 rpm at 25 ± 1 ◦C. Results were recorded only when the torque was within the acceptable range (10--100%) ([@b0220], [@b0235]).

2.3. *In vitro* experiments {#s0040}
---------------------------

### 2.3.1. Cytotoxicity assay {#s0045}

The cytotoxicity assay was performed on NIH-3T3 mouse embryonic fibroblast cells by the MTT (3-(4, 5-dimethyl thiazol-2yl)-2, 5-diphenyl tetrazolium bromide) assay. Briefly, the cells in DMEM medium containing 10% FBS and 1% penicillin--streptomycin were seeded into 96 well plates and incubated at 37 °C for 24--48 h in a humidified atmosphere containing 5% CO~2~. When the desired cell confluence was reached, fresh medium which contained different concentrations of vitexin, chitosan and vitexin containing chitosan dispersion (R1) was added to the wells. At the end of the incubation time, the MTT dye was added and after re-incubation, formazan crystals were dissolved in DMSO. Absorbance of the wells was measured at 570 nm using a spectrometric microplate reader (BioTek Cytation 5, England). Results were expressed as the percentage of inhibition compared with control cells in which cell survival was presumed 100%. All cell viability assays were performed in triplicate ([@b0075]).

### 2.3.2. Wound healing assay {#s0050}

The CytoSelect ™ 24-Well Wound Healing Assay (Cat no: CBA 120) was used to test wound healing activity of vitexin *in vitro*. The study was performed according to the manufacturers\' optimized protocols ([@b0115]). Briefly, using sterile forceps, the desired number of inserts were placed in the plate wells with their "wound field" aligned in the same direction. The cell suspension containing 0.5--1.0 × 10^6^ cells/ml in media containing 10% FBS was added to each well by carefully inserting the pipet tip through the open end at the top of the insert. Cells were cultured until they form a monolayer around the insert. The insert was removed, leaving about 0.9 mm open "wound field" between the cells. The study was performed in two plate for 0 and 72 h incubation. 0th time point indicated that the insert should be removed after 24 h of incubation. At this time vitexin, chitosan and vitexin/chitosan dispersion (R1) were added to second plate wells and incubated for 72 h. At the end of the time point, the wells were stained with cell stain solution. And then the wound closure was monitored with a light microscope (4x magnification) and imaged under brightfield microscope.

2.4. *In vivo* experiments {#s0055}
--------------------------

### 2.4.1. Animals {#s0060}

Male Sprague--Dawley rats (160--180 g) were purchased from Osmangazi University (Eskisehir, Turkey) were used in the experiments. All animals were housed in a well-ventilated room with 12-h light/dark cycles at 22 ± 1 °C and allowed free access to food and water *ad libitum*. The animal study was approved by the Local Ethics Committee of Osmangazi University (Approval Number: 588--2017). Animal care and research protocols were based on the principles and guidelines adopted by the Guide for the Care and Use of Laboratory Animals (NIH publication No: 85--23, revised in 1985).

### 2.4.2. Excisional wound model {#s0065}

The animals were anesthetized with xylazine (2% Alfazines) and 0.08 cm^3^ ketamine (10% Ketasols). The dorsal hairs of the rats were removed by shaving. The circular wound (10--12 mm) was created on the dorsal interscapular region of each animal by excising the skin with scissors. After the wound was created, animals were placed in separate cages to prevent any damages by interactions in between. Animal treatment groups are formed as: control (no treatment), positive control (Madecassol® treatment), vehicle-treated group (chitosan treatment), formulation treated group (chitosan-based gel formulation containing vitexin treatment). Progressive changes in wound areas at the 0th, 7th, 14th and 21st days of treatment were photographed with camera and measured with caliper. All test materials were administered every morning and evening ([@b0015], [@b0225]).

### 2.4.3. Histopathological study {#s0070}

The animals were anesthetized, and the wound area was removed on the 7th, 14th and 21st days of the study from rats for histological analysis. Extracted tissues were stained with hematoxylin and eosin stain (H & E) and Masson Trichrome. Histopathologic changes in dermis and epidermis were detected under microscope. A systematic examination of 20 random fields under 40X magnification was performed in order to semi-quantitatively score the following histological variables (0:none; 1:mild; 2:moderate; 3:severe). Reepithelization, collagen tissue disorganization, neutrophil infiltration, hemorrhage, granulation tissue formation and angiogenesis were taken into consideration while evaluating the histopathological changes in microscopic tissue examination. Scoring was performed by considering these criteria ([@b0125], [@b0005]).

2.5. Statistical analyses {#s0075}
-------------------------

Statistical analyses were performed by using SPSS 18.0 and GraphPad Prism version 5.0 software. Measurement of wound contraction assessment, the differences between groups were analyzed by two-way analysis of variance (ANOVA) and the results were expressed as means ± SEM. Histological analysis were evaluated by Kruskal-Wallis one-way ANOVA on Ranks Teat and results were expressed as means ± SD. Cytotoxicity studies were evaluated with two-way ANOVA and the results were expressed as means ± SEM. Differences were considered significant when *P* ≤ 0.05.

3. Results {#s0080}
==========

3.1. Formulation analysis {#s0085}
-------------------------

The results of pH measurements and rheological analyses of formulations were shown in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}.Table 1Changes in pH values of the gel formulations prepared during the storage period of 1 months (mean ± SE; RH = relative humidity).Storage ConditionStorage DayR1 (Chitosan-based gel formulation containing vitexinF1 (Blank Gel Formulation)**25** ± **1** ◦**C0**4.1 ± 0.13.6 ± 0.05**30**4.1 ± 0.13.6 ± 0.1  **4** ± **1** ◦**C0**4.1 ± 0.13.6 ± 0.05**30**4.1 ± 0.13.7 ± 0.05  **40** ± **1** ◦**C 60%0**4.1 ± 0.13.6 ± 0.05**30**4.2 ± 0.053.8 ± 0.1Table 2Rheological analyses of the R1 and F1 formulations during the storage period of 1 months (RH = relative humidity).Storage ConditionStorage DayR1 (Chitosan-based gel formulation containing vitexinF1 (Blank Gel Formulation)mPamPa**25 ± 1 ◦C0**96459021**30**97859112  **4 ± 1 ◦C0**96459021**30**97569345  **40 ± 1 ◦C 60%0**96459021**30**97539456

3.2. Experiments {#s0090}
----------------

### 3.2.1. Cytotoxicity assay {#s0095}

The dispersions were applied to the cells for 24 and 48 h, with a concentration of 0.5, 1, 2, 5, 10, 20, 30, 50, 75 and 100 μg/mL. As a result, it was observed that the cell viability did not drop below 45% even at the highest dose for 48 h. The results after 24 and 48 h of the cytotoxicity test are shown in [Fig. 1](#f0005){ref-type="fig"}. In the study, the IC50 value for vitexin was 90 μg/mL. In addition, vitexin was dissolved in DMSO. DMSO in the used concentration was seen to have no significant effect in cytotoxicity assay ([@b0105]).Fig. 1NIH-3T3 cell viability results from cells exposed to different concentrations of vitexin, chitosan and vitexin/chitosan dispersions (R1) after 24 h and 48 h incubation. \*(Ι) on figure indicated standard deviation, SD.

### 3.2.2. Wound healing assay {#s0100}

In this study, NIH-3T3 (mouse embryo fibroblast cell line) and HaCaT (human epidermal keratinocyte cell line) cells were selected. The vitexin, chitosan and vitexin/chitosan dispersions were used as 1 μg of vitexin in each well and incubated for 0--72 h in the growth medium. Vitexin and the dispersions were applied after the insert was removed. The wells containing only DMEM medium were used as controls. According to results there were no visually obvious differences between vitexin and chitosan dispersions containing vitexin, but after 72 h, a significant cell migration was observed especially in HaCaT cells and the space was tightly closed. In the NIH-3T3 cells, there was still some space in the control, and a significant cell proliferation was observed in vitexin, chitosan, vitexin/chitosan dispersion ([Fig. 2](#f0010){ref-type="fig"}).Fig. 2Results of wound healing assay performed with NIH-3T3 (mouse embryo fibroblast cell line) and HaCaT (human epidermal keratinocyte cell line) cells.

### 3.2.3. Wound healing construction {#s0105}

The changes in the size of wounds were shown in [Fig. 3](#f0015){ref-type="fig"}. Differentiation of wound area photographed on the 7th, 14th, 21st days and were shown in [Fig. 4](#f0020){ref-type="fig"}. When compared to the control group, progressive healing was observed on wounds in rats treated with vitexin formulation. According to our macroscopic results, it is determined that vitexin formulation was almost as potent as positive control Madecassol®.Fig. 3Wound construction of the macroscopic measurements. Data are means ± SEM. ^\*\*\*^*P* \< 0.001 compared to the control group (n = 6--7).Fig. 4Digital imaging of circular excision wound areas at 0, 7, 14, 21st days.

### 3.2.4. Histopathological results {#s0110}

Histological examinations demonstrated that epidermal and dermal regeneration was promoted by vitexin formulation. When 7-day groups were evaluated, reepithelization was observed in rats in the formulation-treated group. In statistical evaluation of the results of scoring, results from formulation-treated groups were significantly better than the control and chitosan-treated groups. When reepithelization and wound healing were compared in 14-day groups, statistically better results were obtained from the Madecassol® and formulation groups than the control group. Significantly better results were observed in the vitexin formulation group in comparison with the chitosan-treated group. There were no statistically significant changes in the evaluation of 21-day groups. Wound healing was detected in all groups. It was found that vitexin formulation provide reepithelization and wound healing in shorter time ([Table 3](#t0015){ref-type="table"}, [Fig. 5](#f0025){ref-type="fig"}).Table 3Scoring of wound healing in histological examination. Mean of epidermal-dermal regeneration, granulation and angiogenesis. Data are means ± SD. ^aaa^*P* \< 0.001 compared to the control group. ^bbb^*P* \< 0.001 compare to the chitosan group.Mean ± SDMedian (25--75)PMultiple comparison**7^th^DayControl**14,50 ± 0,8415,00 (13,75--15,00)**0,001**1--3, 2--3**Chitosan (F1)**13,83 ± 0,9814,00 (13,50--14,25)**Vitexin Formulation (R1)**8,33 ± 0,82^aaa,\ bbb^8,50 (7,75--9,00)**Madecassol**10,83 ± 1,4710,50 (9,75--12,25)  **14^th^DayControl**9,83 ± 1,1710,00 (8,75--11,00)**0,001**1--3, 1--4, 2--3**Chitosan (F1)**9,33 ± 0,529,00 (9,00--10,00)**Vitexin Formulation (R1)**4,00 ± 1,10^aaa,\ bbb^4,00 (3,50--5,00)**Madecassol**4,83 ± 1,33^aaa^5,00 (3,75--5,50)  **21^st^DayControl**3,83 ± 0,754,00 (3,00--4,25)0,214Ns.**Chitosan (F1)**3,67 ± 1,034,00 (2,75--4,25)**Vitexin Formulation (R1)**2,67 ± 1,212,00 (2,00--3,50)**Madecassol**3,17 ± 1,602,50 (200--4,50)Fig. 5Histological analyses of wound area samples at days 7, 14 and 21.

4. Discussion {#s0115}
=============

Wound healing is known to be a complex and dynamic process that usually involves distinct phases marking the healing stages and requires multiple cell types to complete a variety of cellular activities ([@b0165]). The first phase in wound healing is hemostasis, followed by inflammation phase, proliferative phase and maturation phase. Herbal drugs, along with other drugs are used in wound healing for a long period of time ([@b0170]). Plants affect some of these phases in wound healing by accelerating or easing. In this context, vitexin is one of the well-known flavonoids found in medicinal plants such as *Passiflora* spp and *Crataegus* spp. Vitexin has been shown to have many different pharmacological activities such as antioxidant, anti-inflammatory, and analgesic effects ([@b0140], [@b0030], [@b0190]). In present study it is aimed to investigate the *in vivo* and *in vitro* effects of chitosan-based gel formulation containing vitexin in wound healing. Inflammation phase that starts following the hemostasis phase, is an important and necessary phase for wound healing. In this phase, inflammatory cells (neutrophiles, macrophages *etc.*) immigrate to the wound area and they ensure the removal of microorganisms and tissue residues in the environment. Inflammatory cells are also responsible for the stimulation of fibroblasts and epithelial cells ([@b0180]). Inflammation may be acute or chronic. Acute inflammation contributes to wound healing, while chronic inflammation delays wound healing and prolongs this process ([@b0095]). Vitexin flavonoid used in this study has been shown to have antimicrobial and anti-inflammatory properties in various studies ([@b0090], [@b0040]). Likewise, chitosan in the formulation, is also known to have antioxidant and anti-inflammatory activities ([@b0200]). When evaluating the results of this study, it is observed that chitosan-based gel formulation containing vitexin was more effective compared to control and madecassol-treated groups, especially in 7 and 14th days ([Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"} and [Table 3](#t0015){ref-type="table"}). The tissue renewal in epithelial and dermal tissues were more significant compared to control and chitosan groups, especially in histopathological changes. As seen in histological examinations, it has been seen that chitosan-based gel formulation containing vitexin increases reepithelization and vascularization in damaged tissue ([Table 3](#t0015){ref-type="table"}, [Fig. 5](#f0025){ref-type="fig"}) and this has also been accelerating the wound healing. Similarly, when wound area diameter shrinkage was examined, recovery was faster ([Fig. 3](#f0015){ref-type="fig"}).

The authors believe that their formulation with vitexin which is known to have both antioxidant and anti-inflammatory effects and chitosan accelerate wound healing by exhibiting synergistic activity. Antioxidant substances accelerate wound healing by removing the reactive oxygen species and inflammation products formed during wound healing. In addition, they are thought to contribute to wound healing by preventing the prolongation of the inflammation phase with their anti-inflammatory effects. In a study performed by Kant et al., it was observed that curcumin accelerated wound contraction, decreased the expressions of inflammatory mediators (tumor necros factor-α, interleukin-1β, *etc.*) and also increased the inflammatory cytokine levels ([@b0135]). It is demonstrated that the anti-inflammatory effect of vitexin is exhibited via the inhibition of cytokines, nitric oxide and prostaglandin E~2~ release ([@b0215]).

In our *in vitro* study, MTT assay was used to determine the cytotoxicity of the vitexin on the cells. This test develops a quantitative colorimetric assay via tetrazolium salt of mammalian cell survival and proliferation. It detects living cells. The viability depends on the degree of active cells ([@b0210]). *In vitro* cytotoxicity methods are important test methods in assessing the biocompatibility of a new formulation. Once the effects of the formulations on the cell growth rates in cell cultures have been investigated, clearence of toxicity profiles provides both time and economic advantages. In addition, the cytotoxicity assay of the formulations prepared is of vital importance to ensure that the experimental animals do not present any risk or that the acute toxicity response does not appear ([@b0160]). In this study, NIH-3T3 mouse fibroblast cells were selected because fibroblasts are found in the matrix and connective tissue of the body and are widely used to define cellular cytotoxicity and genotoxicity of many formulations ([@b0045], [@b0205]). The concentrations used in our cytotoxicity study were selected depending on the studies performed in the literature ([@b0245], [@b0240]). Our results showed that the IC50 value for vitexin was 90 μg/mL which indicates the low cytotoxicity of vitexin. Wound healing assay is a standard *in vitro* technique used for the determination of cell migration. In this assay, a cell-free area is created in a unified single layer by removal of cells in the respective region. The important data obtained from the wound healing assay is the rate of gap closure, which is a measure of the speed of the collective movement of the cells ([@b0130]). Moreover, rapid and functional wound closure is the primary target in wound treatment. The wound healing assay is easily used for applications such as small molecule screening and drug discovery ([@b0225], [@b0120], [@b0230]). Quantification of fibroblast proliferation, migration and collagen synthesis in fibroblast cell cultures were first proposed by [@b9000] as a method for testing *in vitro* wound healing activity. This approach has been successfully applied to investigate the development and mechanism of action of new drugs using fibroblast cells with different origins ([@b0145], [@b0010]). In this study, it was observed that the cell migration was relatively faster in formulation containing vitexin compared to vitexin-free chitosan and control groups. Also, there was no visually obvious difference between vitexin-free chitosan and vitexin formulation groups. The difference in cell migration in HaCaT cells is better understood when evaluated in terms of cells.

In conclusion, our test substance chitosan-based gel formulation containing vitexin significantly accelerated wound healing both *in vivo* and *in vitro*. It is thought that anti-oxidant, anti-inflammatory, epithelial tissue regeneration and cell migration enhancing effects of vitexin play a positive role on wound healing. Chitosan also has similar effects on wound healing, which demonstrated synergistic activity with vitexin. Authors believe that usage of chitosan-based gel formulation containing vitexin may raise a new perspective in wound treatment and provide an advantage to modern medicine since the exist topical wound healing medications are limited in markets and also may cause allergic skin reactions. However, further investigation may be required for clinical use.
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